Human butyrylcholinesterase - Altimmune

Drug Profile

Human butyrylcholinesterase - Altimmune

Alternative Names: NEX 91; Protexia; rBChE; rBChE bioscavenger; Recombinant human butyrylcholinesterase

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmAthene
  • Class Antidotes; Butyrates; Cholinesterases
  • Mechanism of Action Scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Poisoning

Highest Development Phases

  • No development reported Alzheimer's disease; Poisoning

Most Recent Events

  • 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
  • 04 May 2017 Altimmune merged with PharmAthene and the combined entity was renamed as Altimmune
  • 08 Sep 2014 Human butyrylcholinesterase - PharmAthene is available for licensing as of 08 Sep 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top